/PRNewswire/ – Haemonetics Corporation announced today expanded roles for two executives. These changes are part of an ongoing plan to advance the Company’s global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO. In this expanded role, Mr. Davies will have overall accountability for the Company’s commercial, product development and product management focus across the entire portfolio and in all geographies.
Byron Selman, who joined the Company upon the acquisition of Pall Corporation’s transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies. Mr. Selman will oversee the Company’s global commercial and market development efforts, with the exception of the Company’s commercial Plasma business.
Mr. Concannon stated: “Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers. These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development.”